Therefore, we investigated prednisolone (GC), tofacitinib (JAK 1/3 inhibitor), tocilizumab (IL-6 receptor blocking Ab), and adalimumab (TNF Ab) in the presence of TCR and RA synovial fluid stimulation. The gene discussed is TNF; the disease is rheumatoid arthritis.